• Home
  • About Us
  • Science
    • Active Immunotherapies
    • Antibodies
  • Our Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Publications

Select the category

  • All Categories
  • Vaccines
  • Immunobody
  • Moditope
  • Antibodies
  • Glymab
  • Avidimab

Select the year

  • All Tags
  • 2024
  • 2023
  • 2022
Clear Filters
U

Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging

February 14, 2022
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 5
No results found.

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.

    Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

    • Follow
    • Follow

    About Us
    Leadership Team
    Science
    Our Pipeline
    News
    Contact Us
    Find a Trial
    Become an Investigator

    ACTIVE IMMUNOTHERAPY

    ImmunoBody®
    Moditope®

    ANTIBODIES

    GlyMab®
    AvidiMab®

    Investors
    Company Profile
    Advisors
    Corporate Governance
    Documents & Presentations
    Share Information
    Financial Information

    Copyright © 2025 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy